Nicki Vasquez sold $61k of STRO
CHIEF PORT. STRAT & ALNCE OFCR at SUTRO BIOPHARMA, INC.. 12,185 shares at an average of $5.00, traded Jan 29, 2024, filed Jan 31, 2024.
Score components
- +15RoleOfficer
- +7Trade size$61k at market
- +10Share of holdings soldSold 49% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-002065, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 29, 2024 | SOpen-market sale Common Stock10b5-1 | -12,185 | $5.00 | $61k | 12,803 | Jan 31, 2024 |
| Jan 29, 2024 | MOption exercise Common Stock10b5-1 | +2,500 | $0.00 | $0 | 15,303 | Jan 31, 2024 |
| Jan 29, 2024 | FTax withholding Common Stock10b5-1 | -1,024 | $4.99 | $5,110 | 14,279 | Jan 31, 2024 |
| Jan 29, 2024 | MOption exercise Restricted Stock Unit (RSU)derivative10b5-1 | -2,500 | $0.00 | $0 | 0 | Jan 31, 2024 |
Related signals
Other insiders at SUTRO BIOPHARMA, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | SUTRO BIOPHARMA, INC. | Gregory K. Chow CFO | $16k 19,750 shares | - | |
| 43Moderate | SUTRO BIOPHARMA, INC. | Jane Chung Chief Executive Officer | $10k 12,500 shares | +11% | |
| 36Weak | SUTRO BIOPHARMA, INC. | Hans-Peter Gerber CHIEF SCIENTIFIC OFFICER | $14k 17,000 shares | +31% | |
| 44Moderate | SUTRO BIOPHARMA, INC. | Connie Matsui director | $40k 50,000 shares | - | |
| 36Weak | SUTRO BIOPHARMA, INC. | David Pauling Chief Admin. Ofcr. & GC | $9,993 12,504 shares | +21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.